MS and Demyelinating Disorders

The chair of the department of neurology at The Ohio State University discussed some of the main themes and takeaways from the MS Virtual 2020 meeting.

The Consortium of Multiple Sclerosis Centers is seeking poster and platform presentations for the 2021 Annual Meeting, which will take place June 2–5, 2021.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai addresses the need for new treatments for MS spasticity.

The director of the neurology residency training program at the Icahn School of Medicine at Mount Sinai addresses the challenges of approving cannabinoid products in the US.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 13, 2020.

Leigh Charvet, PhD, discusses the adoption and potential of validated digital and tele-based approaches for the treatment of multiple sclerosis.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending November 7, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

This three-part, educational webinar series provides evidence-based information about the effects of cannabis on MS symptoms, including pain and spasticity.

Bruce Cree, MD, PhD, MAS, offers his perspective on recent trial results that put to bed a long line of inconsistent data on the utility of high-dose biotin for multiple sclerosis.

A 2-part webcast series geared toward MS nursing professionals and patients.

A 2-part webcast series geared toward MS nursing professionals and patients.

The percent change from baseline was lower in those who initiated ocrelizumab early than those initially on placebo for both T2 lesion volume and T1 hypointense lesion volume.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

The SPI2 study did not replicate the improvements observed in prior study, instead suggesting that biotin (MD1003; MedDay Pharmaceuticals) is ineffective in patients with progressive MS.

The authors noted that research is still needed to establish standards for cell mobilization and immune-conditioning regimens.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

On the heels of successful long-term data, evobrutinib seeks to maintain its high efficacy in 2 pivotal phase 3 clinical trials.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

Here's what is coming soon to NeurologyLive.